NCT03302221

Brief Summary

The objective of the trial was to evaluate velocity-associated parameters of pulsed-wave Doppler ultrasound at induction, discharge from the post-anaesthesia care unit and during inspiratory cough in addition to the consumption of phenylephrine during the operation in patients undergoing video-assisted thoracic surgery with three types of anaesthesia management.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Oct 2017

Typical duration for phase_4 lung-cancer

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 5, 2017

Completed
10 days until next milestone

Study Start

First participant enrolled

October 15, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2020

Completed
Last Updated

March 10, 2020

Status Verified

March 1, 2020

Enrollment Period

2.8 years

First QC Date

October 1, 2017

Last Update Submit

March 6, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Change of end-diastolic velocity

    The primary outcome was the end-diastolic velocity at 12 time points of anaesthesia induction among the three groups.

    baseline and 10 minutes after induction

Secondary Outcomes (2)

  • pulsed-wave Doppler ultrasound

    before leaving the PACU, up to 5 minutes

  • intraoperative consumption of phenylephrine

    through study completion, an average of 3 hours

Study Arms (3)

Group control

OTHER

In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.

Drug: 0.5% ropivacaine local anaesthesia

Paravertebral Block Group

EXPERIMENTAL

In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.

Drug: 0.5% ropivacaine paravertebral block

Epidural Block Group

EXPERIMENTAL

The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block

Drug: 0.25% ropivacaine epidural block

Interventions

The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block

Paravertebral Block Group

A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.

Epidural Block Group

local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.

Group control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ethnic Chinese;
  • age, 18 to 65 years old;
  • American Society of Anaesthesiologists (ASA) physical status I or II;
  • required VATS for lung surgery and one lung ventilation .

You may not qualify if:

  • body mass index exceeding 30 kg/m2; Patients with a history of hypertension, diabetes mellitus or arteriosclerosis; and any allergy to drugs used in the study.
  • Patients with arrhythmias or implanted cardiac pacemakers were excluded. Patients with diseases of the central or peripheral nervous system were excluded.
  • Patients taking medications affecting the autonomic nervous system, such as b-blockers and calcium channel blockers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the First Hospital of China Medical University

Shenyang, Liaoning, 110001, China

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Hong Ma, MD,PhD

    Department of Anesthesiology

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Doppler Ultrasonography Assessed Vascular Changes
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate proffesor

Study Record Dates

First Submitted

October 1, 2017

First Posted

October 5, 2017

Study Start

October 15, 2017

Primary Completion

August 20, 2020

Study Completion

September 20, 2020

Last Updated

March 10, 2020

Record last verified: 2020-03

Locations